Abstract:Background: Methylation plays a significant role in the etiology and pathogenesis of hepatocellular carcinoma (HCC). The aim of the present study is to identify aberrantly methylated-diferentially expressed genes (DEGs) and dysregulated pathways associated with the development of HCC through integrated analysis of gene expression and methylation microarray. Method: Aberrantly methylated-DEGs were identified from gene expression microarrays (GSE62232, GSE74656) and gene methylation microarrays (GSE44909, GSE57958). Functional enrichment and pathway enrichment analyses were performed through the database of DAVID. Protein-protein interaction (PPI) network was established by STRING and visualized in Cytoscape. Subsequently, overall survival (OS) analysis of hub genes was performed by OncoLnc. Finally, we validated the expression level of CDCA5 by quantitative real-time PCR (qRT-PCR) and western blotting, and performed Immunohistochemical experiments utilizing a tissue microarray. Cell growth assay and flow cytometry were behaved to explore the function of CDCA5. Results: Aberrantly methylated-DEGs were enriched in biological process, molecular function, cellular component and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. Among them, cell cycle was enriched most frequently, and some terms associated with cancer were enriched, such as p53 signaling pathway, pathways in cancers, PI3K-Akt signaling pathway and AMPK signaling pathway. After survival analysis and validation in TCGA database including methylation and gene expression status, 12 hub genes were identified. Furthermore, the expression level of new gene CDCA5 was validated in HCC cell lines and hepatic normal cell lines through qRT-PCR and western blotting. In additional, immunohistochemistry experiments revealed higher CDCA5 protein expression from HCC tumor tissues compared with paracancer tissues by tissue microarray. Finally, through loss of function, we demonstrated that CDCA5 promoted proliferation by regulating the cell cycle. Conclusions: In summary, the present study implied possible aberrantly methylated-differentially expressed genes and dysregulated pathways in HCC by bioinformatics analysis and experiments, which could be helpful in understanding the molecular mechanisms underlying the development and progression of HCC. Hub genes including CDC20, AURKB, BIRC5, RRM2, MCM2, PTTG1, CDKN2A, NEK2, CENPF, RACGAP1, GNA14 and especially the new gene CDCA5 may serve as biomarkers for diagnosis, treatment and prognosis of HCC.

Laser Capture Microdissection Combined with Proteome Analysis in Determining Differential Expression of DDAH-1 in Hepatocellular Carcinoma

Genes Encoding Pir51, Beclin 1, RbAp48 and Aldolase B Are Up or Down-Regulated in Human Primary Hepatocellular Carcinoma.

Proteomic Analysis of Hepatocellular Carcinoma and Cholangiocarcinoma by Laser Capture Microdissection

Laser capture microdissection in comparative proteomic analysis of hepatocellular carcinoma

Aberrant DNA Methylation Patterns of Deleted in Liver Cancer 1 Isoforms in Hepatocellular Carcinoma

Comparative proteomics and molecular mechanical analysis in CDA-II induced therapy of LCI-D20 hepatocellular carcinoma model

Proteomic Fingerprinting of N-linked Glycoproteins Involved in Hepatocellular Carcinoma

Proteome Analysis of Hepatocellular Carcinoma by Two-dimensional Difference Gel Electrophoresis

[Gene Expressions of DNA Methyltransferase 1 and Human Leukocyte Antigen-Dralpha in Hepatocelluar Carcinoma and Their Clinical Significance].

Aberrantly DNA Methylated-Differentially Expressed Genes and Pathways in Hepatocellular Carcinoma

Analysis of Low Abundance Diferential Proteins in Plasma from Hepatocellular Carcinomas Patients by Multi-dimensional Chromatography Tandem Mass Spectrometry

A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values

Tandem Mass Tag-Based Proteomic Analysis of Potential Biomarkers for Hepatocellular Carcinoma Differentiation

Proteomic and Phosphor-Proteomic Signatures of Clinical Hepatitis B Virus-Associated Hepatocellular Carcinoma

Potential Diagnostic and Prognostic Marker Dimethylglycine Dehydrogenase (DMGDH) Suppresses Hepatocellular Carcinoma Metastasis in Vitro and in Vivo

Proteome Analysis of Hepatocellular Carcinoma Cell Strains, MHCC97-H and MHCC97-L, with Different Metastasis Potentials.

Identification and Comparison of Differentiation-Related Proteins in Hepatocellular Carcinoma Tissues by Proteomics

Differential Proteome Analysis Of Hepatitis B Virus-Related Hepatocellular Carcinoma With And Without Cirrhosis From Formalin-Fixed And Paraffin-Embedded Tissue Samples

Difference Gel Electrophoresis Based Differential Proteomic Analysis of Hepatocellular Carcinoma Cell Lines with Different Metastasis Potential

Quantitative Proteomic Analysis for High-Throughput Screening of Differential Glycoproteins in Hepatocellular Carcinoma Serum

Proteomic profiling of hepatitis B virus-related hepatocellular carcinoma in China: a SELDI-TOF-MS study